In-vitro assessment of platelet function

Transfusion and Apheresis Science

Volumn 44, Issue 3, 2011, Pages 305-319

  Picker, Susanne M ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Bleeding time; PFA 100; Platelet aggregometry; Platelet apoptosis; Platelet function; Platelet metabolism; Platelet mitochondrial function; Shear induced platelet adhesion; Thrombelastography

Indexed keywords

ACETIC ACID; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; BICARBONATE; CLOPIDOGREL; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; FLUORESCENT DYE; GLYCOPROTEIN; GLYCOPROTEIN IB; HEPARIN; HYPOTONIC SOLUTION; MONOCLONAL ANTIBODY; PHOSPHATE; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PSORALEN; PURINERGIC P2Y12 RECEPTOR ANTAGONIST; PURINERGIC RECEPTOR BLOCKING AGENT; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANTICOAGULANT THERAPY; APOPTOSIS; ARTICLE; BERNARD SOULIER DISEASE; BLEEDING; BLEEDING TIME; BLOOD CLOTTING; BLOOD CLOTTING TEST; BLOOD EXAMINATION; BLOOD SAMPLING; CELL STRUCTURE; CELL SURVIVAL; DRUG EFFICACY; DRUG INHIBITION; ELECTRON MICROSCOPY; ELECTROPHORESIS; FLOW CYTOMETRY; HEMOSTASIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIGHT TRANSMISSION AGGREGOMETRY; PARTIAL THROMBOPLASTIN TIME; PHLEBOTOMY; PROGNOSIS; PUVA; SCOTT SYNDROME; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SPECTROPHOTOMETRY; SURGICAL RISK; THROMBELASTOMETRY; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE COUNT; THROMBOCYTE DISORDER; THROMBOCYTE FUNCTION; THROMBOCYTE METABOLISM; THROMBOCYTE PRESERVATION; THROMBOCYTE TRANSFUSION; THROMBOELASTOGRAPHY; THROMBOEMBOLISM; TURBIDIMETRY;

BLOOD PLATELETS; BLOOD PRESERVATION; HUMANS; PLATELET FUNCTION TESTS; PLATELET TRANSFUSION;

EID: 79958709010     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2011.03.006     Document Type: Article

References (155)

1. Butkiewicz A.M., Kemona H., Dymicka-Piekarska V., Matowicka-Karna J., Radziwon P., Lipska A. Platelet count, mean platelet volume and thrombocytopoietic indices in healthy women and men. Thromb Res 2006, 118:199-204.
2. Li J., Xia Y., Bertino A.M., Coburn J.P., Kuter D.J. The mechanism of apoptosis in human platelets during storage. Transfusion 2000, 40:1320-1329.
3. Cardigan R., Turner C., Harrison P. Current methods of assessing platelet function: relevance to transfusion medicine. Vox Sang 2005, 88:153-163.
4. Akkerman J.W. Regulation of carbohydrate metabolism in platelets: a review. Thromb Haemost 1978, 39:12-24.
5. Gorlin J.B. Standards for blood banks and transfusion services, 21th ed. 2002, American Association of Blood Banks, Bethesda, Maryland, USA.
6. Council of Europe. Guide to the preparation, use and quality assurance of blood components, 15th ed. Strassbourg, France, Council of Europe Publishing; 2009.
7. Klouche M. Diagnostic methods for platelet function analysis. Transfus Med Hemother 2007, 34:20-32.
8. Wakamoto S., Fujihara M., Kuzuma K., Sato S., Kato T., Naohara T., et al. Biologic activity of RANTES in apheresis PLT concentrates and its involvement in nonhemolytic transfusion reactions. Transfusion 2003, 43:1038-1046.
9. Apelseth T.O., Hervig T.A., Wetzel-Larsen T., Bruserud Ø. Cytokine accumulation in photochemically treated and gamma-irradiated platelet concentrates during storage. Transfusion 2006, 46:800-810.
10. Klüter H., Bubel S., Kirchner H., Wilhelm D. Febrile and allergic transfusion reactions after the transfusion of white cell-poor platelet preparations. Transfusion 1999, 39:1179-1184.
11. Cattaneo M. Inherited platelet-based bleeding disorders. J Thromb Haemost 2003, 1:1628-1638.
12. Ruggeri Z.M. Platelets in atherothrombosis. Nat Med 2002, 8:1227-1234.
13. Rand L.M., Leung R., Packham M.A. Platelet function assays. Transfus Apher Sci 2003, 28:303-317.
14. Harrison P. Platelet function analysis. Blood Rev 2005, 19:111-123.
15. Ryningen A., Apelseth T., Hausken T., Bruserud Ø. Reticulated platelets are increased in chronic myeloproliferative disorders, pure erythrocytosis, reactive thrombocytosis and prior to hematopoietic reconstitution after intensive chemotherapy. Platelets 2006, 17:296-302.
16. Salvagno G.L., Montagnana M., Degan M., Marradi P.L., Ricetti M.M., Riolfi P., et al. Evaluation of platelet turnover by flow cytometry. Platelets 2006, 17:170-177.
17. McCabe D.J., Harrison P., Sidhu P.S., Brown M.M., Machin S.J. Circulating reticulated platelets in the early and late phases after ischaemic stroke and transient ischaemic attack. Br J Haematol 2004, 126:861-869.
18. Chaoui D., Chakroun T., Robert F., Rio B., Belhocine R., Legrand O., et al. Reticulated platelets: a reliable measure to reduce prophylactic platelet transfusions after intensive chemotherapy. Transfusion 2005, 45:766-772.
19. Peddinghaus M.E., Tormey C.A. Platelet-related bleeding: an update on diagnostic modalities and therapeutic options. Clin Lab Med 2009, 29:175-191.
20. Becchi C., Al Malyan M., Fabbri L.P., Marsili M., Boddi V., Boncinelli S. Mean platelet volume trend in sepsis: is it a useful parameter?. Minerva Anestesiol 2006, 72:749-756.
21. Gohda F., Uchiumi H., Handa H., Matsushima T., Tsukamoto N., Morita K., et al. Identification of inherited macrothrombocytopenias based on mean platelet volume among patients diagnosed with idiopathic thrombocytopenia. Thromb Res 2007, 119:741-746.
22. Fijnheer R., Pietersz R.N., de Korte D., Roos D. Monitoring of platelet morphology during storage of platelet concentrates. Transfusion 1989, 29:36-40.
23. Bowles K.M., Cooke L.J., Richards E.M., Baglin T.P. Platelet size has diagnostic predictive value in patients with thrombocytopenia. Clin Lab Haematol 2005, 27:370-373.
24. Rothwell S.W., Maglasang P., Reid T.J., Gorogias M., Krishnamurti C. Correlation of in vivo and in vitro functions of fresh and stored human platelets. Transfusion 2000, 40:988-993.
25. Holme S. Storage and quality assessment of platelets. Vox Sang 1998, 74:207-216.
26. Bertolini F., Murphy S. A multicenter inspection of the swirling phenomenon in platelet concentrates prepared in routine practice. biomedical excellence for safer transfusion (BEST) working party of the international society of blood transfusion. Transfusion 1996, 36:128-132.
27. Lindahl T.L., Ramström S. Methods for evaluation of platelet function. Transfus Apher Sci 2009, 41:121-125.
28. Murphy S., Rebulla P., Bertolini F., Holme S., Moroff G., Snyder E., et al. In vitro assessment of the quality of stored platelet concentrates. Trans Med Rev 1994, 8:29-36.
29. Murphy S. Metabolic patterns of platelets - impact on storage for transfusion. Vox Sang 1994, 67(Suppl. 3):271-273.
30. Kim B.K., Baldini M.G. The platelet response to hypotonic shock. Its value as an indicator of platelet viability after storage. Transfusion 1974, 14:130-138.
31. Valeri C.R., Feingold H., Marchionni L.D. The relation between response to hypotonic stress and the 51Cr recovery in vivo of preserved platelets. Transfusion 1974, 14:331-337.
32. Okada Y., Maeno E., Shimizu T., Dezaki K., Wang J., Morishima S. Receptor-mediated control of regulatory volume decrease (RVD) and apoptotic volume decrease (AVD). J Physiol 2001, 532:3-16.
33. Hesse J., Doll M., Wilhelm M., Seitz R., Heiden M. Assessment of platelet function in applications for marketing authorization. Infus Ther Transfus Med 2001, 28:44-50.
34. Picker S.M., Speer R., Gathof B.S. Functional characteristics of buffy-coat PLTs photochemically treated with amotosalen-HCl for pathogen inactivation. Transfusion 2004, 44:320-329.
35. Picker S.M., Steisel A., Gathof B.S. Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units. Transfusion 2008, 48:1685-1692.
36. Picker S.M., Steisel A., Gathof B.S. Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: results of a three-arm in vitro study. Transfus Apher Sci 2009, 40:79-85.
37. Picker S.M., Oustianskaia L., Schneider V., Gathof B.S. Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction. Vox Sang 2009, 97:26-33.
38. Picker S.M., Schneider V., Oustianskaia L., Gathof B.S. Cell viability during platelet storage in correlation to cellular metabolism after different pathogen reduction technologies. Transfusion 2009, 49:2311-2318.
39. Picker S.M., Oustianskaia L., Schneider V., Gathof B.S. Annexin V release and transmembrane mitochondrial potential during storage of apheresis-derived platelets treated for pathogen reduction. Transfus Med Hemother 2010, 37:7-12.
40. Lind SE. The bleeding time. Platelets 2002, 283-289. Academic Press, San Diego. A.D. Michelson (Ed.).
41. Jennings I., Woods T.A., Kitchen S., Walker I.D. Platelet function testing: practice among UK National External Quality Assessment Scheme for Blood Coagulation participants, 2006. J Clin Pathol 2008, 61:950-954.
42. Rodgers R.P., Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost 1990, 16:1-20.
43. Lehman C.M., Blaylock R.C., Alexander D.P., Rodgers G.M. Discontinuation of the bleeding time test without detectable adverse clinical impact. Clin Chem 2001, 47:1204-1211.
44. Elwood P.C., Pickering J., Yarnell J., O'Brien J.R., Ben Shlomo Y., Bath P. Bleeding time, stroke and myocardial infarction: the Caerphilly prospective study. Platelets 2003, 14:139-141.
45. Harrison P. Assessment of platelet function in the labaratory. Hämostaseologie 2009, 1:25-31.
46. Kratzer M.A., Born G.V. Simulation of primary haemostastis in vitro. Haemostasis 1985, 15:357-362.
47. Francis J.L., Francis D., Larson L. Can the platelet function analyzer (PFA-100) substitute for the bleeding time in routine clinical practice. Platelets 1999, 10:132-136.
48. Posan E., McBane R.D., Grill D.E., Motsko C.L., Nichols W.L. Comparison of PFA-100 testing and bleeding time for detecting platelet hypofunction and von Willebrand disease in clinical practice. Thromb Haemost 2003, 90:483-490.
49. Sié P., Steib A. Central laboratory and point of care assessment of perioperative hemostasis. Can J Anaesth 2006, 53(Suppl):S12-S20.
50. Bevilacqua S., Alkodami A.A., Volpi E., Cerillo A.G., Berti S., Glauber M., et al. Risk stratification after coronary artery bypass surgery by a point-of-care test of platelet function. Ann Thorac Surg 2009, 87:496-502.
51. Crescente M., Di Castelnuovo A., Iacoviello L., Vermylen J., Cerletti C., de Gaetano G. Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. Thromb Haemost 2008, 99:14-26.
52. Hézard N., Metz D., Nazeyrollas P., Droulle C., Elaerts J., Potron G., et al. Use of the PFA-100 apparatus to assess platelet function in patients undergoing PTCA during and after infusion of c7E3 Fab in the presence of other antiplatelet agents. Thromb Haemost 2000, 83:540-544.
53. Mani H., Linnemann B., Luxembourg B., Kirchmayr K., Lindhoff-Last E. Response to aspirin and clopidogrel monitored with different platelet function methods. Platelets 2006, 17:303-310.
54. Cattaneo M., Federici A.B., Lecchi A., Agati B., Lombardi R., Stabile F., et al. Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease. Thromb Haemost 1999, 82:35-39.
55. Podda G.M., Bucciarelli P., Lussana F., Lecchi A., Cattaneo M. Usefulness of PFA-100 testing in the diagnostic screening of patients with suspected abnormalities of hemostasis: comparison with the bleeding time. J Thromb Haemost 2007, 5:2393-2398.
56. Kottke-Marchant K., Powers J.B., Brooks L., Kundu S., Christie D.J. The effect of antiplatelet drugs, heparin, and preanalytical variables on platelet function detected by the platelet function analyzer (PFA-100). Clin Appl Thromb Hemost. 1999, 5:122-130.
57. Carcao M.D., Blanchette V.S., Stephens D., He L., Wakefield C.D., Butchart S., et al. Assessment of thrombocytopenic disorders using the Platelet Function Analyzer (PFA-100). Br J Haematol 2002, 117:961-964.
58. Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 2001, 138:152-163.
59. Addad F., Chakroun T., Abderazek F., Ben-Farhat M., Hamdi S., Dridi Z., et al. Response variability to aspirin and one-year prediction of vascular events in patients with stable coronary artery disease. J Thromb Thrombolysis 2010, 29:108-113.
60. Andersen K., Hurlen M., Arnesen H., Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2002, 108:37-42.
61. Macchi L., Sorel N., Christiaens L. Aspirin resistance. definitions, mechanisms, prevalence, and clinical significance. Curr Pharm Des 2006, 12:251-258.
62. Hayward C.P., Harrison P., Cattaneo M., Ortel T.L., Rao A.K. Platelet physiology subcommittee of the scientific and standardization committee of the international society on thrombosis and haemostasis. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006, 4:312-319.
63. Jilma-Stohlawetz P., Hergovich N., Homoncik M., Dzirlo L., Horvath M., Janisiw M., et al. Impaired platelet function among platelet donors. Thromb Haemost 2001, 86:880-886.
64. Paglieroni T.G., Janatpour K., Gosselin R., Crocker V., Dwyre D.M., MacKenzie M.R., et al. Platelet function abnormalities in qualified whole-blood donors: effects of medication and recent food intake. Vox Sang 2004, 86:48-53.
65. Harrison P., Segal H., Furtado C., Verjee S., Sukhu K., Murphy M.F. High incidence of defective high-shear platelet function among platelet donors. Transfusion 2004, 44:764-770.
66. Jilma-Stohlawetz P., Horvath M., Eichelberger B., Koren D., Jilma B., Panzer S. Platelet function under high-shear conditions from platelets concentrates. Transfusion 2008, 48:129-135.
67. Shenkman B., Savion N., Dardik R., Tamarin I., Varon D. Testing of platelet deposition on polystyrene surface under flow conditions by the cone and plate(let) analyzer: role of platelet activation, fibrinogen and von Willebrand factor. Thromb Res 2000, 99:353-361.
68. Varon D., Savion N. Impact cone and plate(let) analyzer. Platelets 2007, 535-544. Academic Press, San Diego. A.D. Michelson (Ed.).
69. Panzer S., Eichelberger B., Koren D., Kaufmann K., Male C. Monitoring survival and function of transfused platelets in Bernard-Soulier syndrome by flow cytometry and a cone and plate(let) analyzer (Impact-R). Transfusion 2007, 47:103-106.
70. Panzer S., Rieger M., Vormittag R., Eichelberger B., Dunkler D., Pabinger I. Platelet function to estimate the bleeding risk in autoimmune thrombocytopenia. Eur J Clin Invest 2007, 37:814-819.
71. Matetzky S., Shankman B., Guetta V., Shechter M., Bienart R., Goldenberg I., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004, 109:3171-3175.
72. Shenkman B., Schneiderman J., Tamarin I., Kotev-Emeth S., Savion N., Varon D. Testing the effect of GPIIb-IIIa antagonist in patients undergoing caroid stenting: correlation between standard aggregometry, flow cytometry and the cone and plate(let) analyzer (CPA) methods. Thromb Res 2001, 311-317.
73. Shenkman B., Matetzky S., Fefer P., Hod H., Einav Y., Lubetsky A., et al. Variable responsiveness to clopidogrel and aspirin among patients with acute coronary syndrome as assessed by platelet function tests. Thromb Res 2008, 122:336-345.
74. Kenet G., Lubetsky A., Shenkman B., Tamarin I., Dardik R., Rechavi G., et al. Cone and platelet analyzer (CPA): a new test for the prediction of bleeding among thrombocytopenic patients. Br J Haematol 1998, 101:255-259.
75. Osende J.I., Fuster V., Lev E.I., Shimbo D., Rauch U., Marmur J.D., et al. Testing platelet activation with a shear-dependent platelet function test versus aggregation-based tests: relevance for monitoring long-term glycoprotein IIb/IIIa inhibition. Circulation 2007, 103:1488-1491.
76. Morrison A., Hornsey V.S., Prowse C.V., MacGregor I.R. Use of the DiaMed Impact R to test platelet function in stored platelet concentrates. Vox Sang 2007, 93:166-172.
77. Gerrah R., Brill A., Tshori S., Lubetsky A., Merin G., Varon D. Using cone and plate(let) analyzer to predict bleeding in cardiac surgery. Asian Cardiovasc Thorac Ann 2006, 14:310-315.
78. Picker S.M., Schneider V., Gathof B.S. Platelet function assessed by shear-induced deposition of split triple-dose apheresis concentrates treated with pathogen reduction technologies. Transfusion 2009, 49:1224-1232.
79. Kostelijk E.H., Folman C.C., Gouwerok C.W., Kramer C.M., Verhoeven A.J., de Korte D. Increase in glycocalicin levels in platelet concentrates stored in plasma or synthetic medium for 8 days: comparison with other platelet activation markers. Vox Sang 2000, 79:21-26.
80. Rognoni F., Viganò V., Colombo Pirola L. Influence of platelet anti-aggregants on mitochondrial respiration of platelets. Boll Soc Ital Cardiol 1977, 22:2140-2146.
81. Abou-Khalil S., Abou-Khalil W.H., Yunis A.A. Mechanism of interaction of ticlopidine and its analogues with the energy-conserving mechanism in mitochondria. Biochem Pharmacol 1986, 35:1855-1859.
82. Abou-Khalil W.H., Lim L.O., Yunis A.A., Abou-Khalil S. Effects of ticlopidine, a new platelet antiaggregating agent, and its analogues on mitochondrial metabolism. Oxidative phosphorylation, protein synthesis and DNA polymerase activity. Biochem Pharmacol 1984, 33:3893-3898.
83. Born G.V.R., Cross M.J. The aggregation of blood platelets. J Physiol 1963, 168:178-195.
84. Kulkarni S., Dopheide S.M., Yap C.L., Ravanat C., Freund M., Mangin P., et al. A revised model of platelet aggregation. J Clin Invest 2000, 105:783-791.
85. Cauwenberghs S., Feijge M.A., Theunissen E., Heemskerk J.W., van Pampus E.C., Curvers J. Novel methodology for assessment of prophylactic platelet transfusion therapy by measuring increased thrombus formation and thrombin generation. Br J Haematol 2007, 136:480-490.
86. Turitto V.T., Weiss H.J. Red blood cells: their dual role in thrombus formation. Science 1980, 207:541-543.
87. Turitto V.T., Baumgartner H.R. Platelet interaction with subendothelium in a perfusion system: physical role of red blood cells. Microvasc Res 1995, 9:335-344.
88. Aarts P.A., van den Broek S.A., Prins G.W., Kuiken G.D., Sixma J.J., Heethaar R.M. Blood platelets are concentrated near the wall and red blood cells, in the center in flowing blood. Arteriosclerosis 1988, 8:819-824.
89. Murphy S., Gardner F.H. Platelet storage at 22°C; metabolic, morphologic, and functional studies. J Clin Invest 1971, 50:370-377.
90. Kattlove H.E., Alexander B., White F. The effect of cold on platelets. II. Platelet function after short-term storage at cold temperatures. Blood 1972, 40:688-696.
91. Miyaji R., Sakai M., Urano H., Nakata K., Sakamoto H., Shirahata A. Decreased platelet aggregation of platelet concentrate during storage recovers in the body after transfusion. Transfusion 2004, 44:891-899.
92. Craft R.M., Chavez J.J., Snider C.C., Muenchen R.A., Carroll R.C. Comparison of modified Thrombelastograph and Plateletworks whole blood assays to optical platelet aggregation for monitoring reversal of clopidogrel inhibition in elective surgery patients. J Lab Clin Med 2005, 145:309-315.
93. Lennon M.J., Gibbs N.M., Weightman W.M., McGuire D., Michalopoulos N. A comparison of plateletworks and platelet aggregometry for the assessment of aspirin-related platelet dysfunction in cardiac surgical patients. J Cardiothorac Vasc Anesth 2004, 18:136-140.
94. Smith J.W., Steinhubl S.R., Lincoff A.M., Coleman J.C., Lee T.T., Hillman R.S., et al. Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation 1999, 99:620-625.
95. Nicholson N.S., Panzer-Knodle S.G., Haas N.F., Taite B.B., Szalony J.A., Page J.D., et al. Assessment of platelet function assays. Am Heart J 1998, 135:S170-S178.
96. Tóth O., Calatzis A., Penz S., Losonczy H., Siess W. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 2006, 96:781-7882.
97. Velik-Salchner C., Maier S., Innerhofer P., Streif W., Klingler A., Kolbitsch C., et al. Point-of-care whole blood impedance aggregometry versus classical light transmission aggregometry for detecting aspirin and clopidogrel: the results of a pilot study. Anesth Analg 2008, 107:1798-1806.
98. Breugelmans J., Vertessen F., Mertens G., Gadisseur A., der Planken M.V. Multiplate whole blood impedance aggregometry: a recent experience. Thromb Haemost 2008, 100:725-726.
99. Neubauer H., Lask S., Engelhardt A., Mügge A. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification. Thromb Haemost 2008, 99:357-362.
100. Siller-Matula J., Schrör K., Wojta J., Huber K. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thromb Haemost 2007, 97:385-393.
101. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Alfonso F., Macaya C., Bass T.A., et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007, 49:1505-1516.
102. Sibbing D., Braun S., Morath T., Mehilli J., Vogt W., Schömig A., et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009, 53:849-856.
103. Pedersen S.B., Grove E.L., Nielsen H.L., Mortensen J., Kristensen S.D., Hvas A.M. Evaluation of aspirin response by multiplate whole blood aggregometry and light transmission aggregometry. Platelets 2009, 20:415-420.
104. Siller-Matula J.M., Christ G., Lang I.M., Delle-Karth G., Huber K., Jilma B. Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay. J Thromb Haemost 2010, 8:351-359.
105. Woo K.S., Kim B.R., Kim J.E., Goh R.Y., Yu L.H., Kim M.H., et al. Determination of the prevalence of aspirin and clopidogrel resistances in patients with coronary artery disease by using various platelet-function tests. Korean J Lab Med 2010, 30:460-468.
106. Hanke A.A., Roberg K., Monaca E., Sellmann T., Weber C.F., Rahe-Meyer N., et al. Impact of platelet count on results obtained from multiple electrode platelet aggregometry (Multiplate). Eur J Med Res 2010, 15:214-219.
107. Rahe-Meyer N., Winterhalter M., Boden A., Froemke C., Piepenbrock S., Calatzis A., et al. Platelet concentrates transfusion in cardiac surgery and platelet function assessment by multiple electrode aggregometry. Acta Anaesthesiol Scand 2009, 53:168-175.
108. Mengistu A.M., Wolf M.W., Boldt J., Röhm K.D., Lang J., Piper S.N. Evaluation of a new platelet function analyzer in cardiac surgery: a comparison of modified thromboelastography and whole-blood aggregometry. J Cardiothorac Vasc Anesth 2008, 22:40-46.
109. Morel-Kopp M.C., Aboud M., Tan C.W., Kulathilake C., Ward C. Whole blood impedance aggregometry detects heparin-induced thrombocytopenia antibodies. Thromb Res 2010, 125:234-239.
110. Ostrowski S.R., Bochsen L., Windeløv N.A., Salado-Jimena J.A., Reynaerts I., Goodrich R.P., et al. Hemostatic function of buffy coat platelets in additive solution treated with pathogen reduction technology. Transfusion 2011, 51:344-356.
111. Jilma-Stohlawetz P., Eichelberger B., Horvath M., Jilma B., Panzer S. In vitro platelet function of platelet concentrates prepared using three different apheresis devices determined by impedance and optical aggregometry. Transfusion 2009, 49:1564-1568.
112. Wang J.C., Aucoin-Barry D., Manuelian D., Monbouquette R., Reisman M., Gray W., et al. Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. Am J Cardiol 2003, 92:1492-1494.
113. Malinin A., Pokov A., Spergling M., Defranco A., Schwartz K., Schwartz D., et al. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb Res 2007, 119:277-284.
114. Paniccia R., Antonucci E., Gori A.M., Marcucci R., Giglioli C., Antoniucci D., et al. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost 2007, 1839-1847.
115. Price M.J., Endemann S., Gollapudi R.R., Valencia R., Stinis C.T., Levisay J.P., et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008, 29:992-1000.
116. Steinhubl S.R., Talley J.D., Braden G.A., Tcheng J.E., Casterella P.J., Moliterno D.J., et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001, 103:2572-2578.
117. Marcucci R., Gori A.M., Paniccia R., Giusti B., Valente S., Giglioli C., et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009, 119:237-242.
118. Saw J., Madsen E.H., Chan S., Maurer-Spurej E. The ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) study. J Am Coll Cardiol 2008, 52:1826-1833.
119. van Werkum J.W., Harmsze A.M., Elsenberg E.H., Bouman H.J., ten Berg J.M., Hackeng C.M. The use of the VerifyNow system to monitor antiplatelet therapy: a review of the current evidence. Platelets 2008, 19:479-488.
120. Mobley J.E., Bresee S.J., Wortham D.C., Craft R.M., Snider C.C., Carroll R.C. Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization. Am J Cardiol 2004, 93:456-458.
121. Michelson A.D., Frelinger A.L., Furman M.I. Current options in platelet function testing. Am J Cardiol 2006, 98:S4-S10.
122. Luddington R.J. Thrombelastography/thromboelastometry. Clin Lab Haematol 2005, 27:81-90.
123. Hartert H. Blutgerinnungsstudien mit der Thrombelastographie, einem neuen Untersuchungsverfahren. Klin Wochenschr 1948, 26:577-583.
124. Lang T., Bauters A., Braun S.L., Pötzsch B., von Pape K.W., Kolde H.J., et al. Multi-centre investigation on reference ranges for ROTEM thromboelastometry. Blood Coagul Fibrinolysis 2005, 16:301-310.
125. Cammerer U., Dietrich W., Rampf T., Braun S.L., Richter J.A. The predictive value of modified computerized thromboelastography and platelet function analysis for postoperative blood loss in routine cardiac surgery. Anesth Analg 2003, 96:51-57.
126. Gutensohn K., Geidel K., Kroeger N., Eifrig B., Crespeigne N., Kuehnl P. Platelet function testing in apheresis products: flow cytometric, resonance thrombographic (RTG) and rotational thrombelastographic (roTEG) analyses. Transfus Apher Sci 2002, 26:147-155.
127. Becker R.C., Tracy R.P., Bovill E.G., Mann K.G., Ault K. The clinical use of flow cytometry for assessing platelet activation in acute coronary syndromes. TIMI-III thrombosis and anticoagulation group. Coron Artery Dis 1994, 5:339-345.
128. Furman M.I., Benoit S.E., Barnard M.R., Valeri C.R., Borbone M.L., Becker R.C., et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 1998, 31:352-358.
129. Janes S.L., Kyle P.M., Redman C., Goodall A.H. Flow cytometric detection of activated platelets in pregnant women prior to the development of pre-eclampsia. Thromb Haemost 1995, 74:1059-1063.
130. Devine D.V., Andestad G., Nugent D., Carter C.J. Platelet-associated factor XIII as a marker of platelet activation in patients with peripheral vascular disease. Arterioscler Thromb 1993, 13:857-862.
131. Grau A.J., Ruf A., Vogt A., Lichy C., Buggle F., Patscheke H., et al. Increased fraction of circulating activated platelets in acute and previous cerebrovascular ischemia. Thromb Haemost 1998, 80:298-301.
132. Scharf R.E., Tomer A., Marzec U.M., Teirstein P.S., Ruggeri Z.M., Harker L.A. Activation of platelets in blood perfusing angioplasty-damaged coronary arteries. Flow cytometric detection. Arterioscler Thromb 1992, 12:1475-1487.
133. Michelson A.D., Barnard M.R., Krueger L.A., Freilinger A.L., Furman M.I. Flow cytometry. Patelets 2002, 297-315. Academic Press, San Diego. A.D. Michelson (Ed.).
134. Michelson A.D., Furman M.I. Laboratory markers of platelet activation and their clinical significance. Curr Opin Hematol 1999, 6:342-348.
135. Hoffmeister K.M., Felbinger T.W., Falet H., Denis C.V., Bergmeier W., Mayadas T.N., et al. The clearance mechanism of chilled blood platelets. Cell 2003, 112:87-97.
136. Lozano M.L., Rivera J., Gónzález-Conejero R., Moraleda J.M., Vicente V. Loss of high-affinity thrombin receptors during platelet concentrate storage impairs the reactivity of platelets to thrombin. Transfusion 1997, 37:368-375.
137. Holme S., Sweeney J.D., Sawyer S., Elfath M.D. The expression of P-selectin during collection, processing, and storage of platelet concentrates: relationship to loss of in vivo viability. Transfusion 1997, 37:12-17.
138. Metcalfe P., Williamson L.M., Reutelingsperger C.P., Swann I., Ouwehand W.A., Goodall A.H. Activation during preparation of therapeutic platelets affects deterioration during storage: a comparative flow cytometric study of different production methods. Br J Haematol 1997, 98:86-95.
139. Leytin V., Allen D.J., Gwozdz A., Garvey B., Freedman J. Role of platelet surface glycoprotein Ibalpha and P-selectin in the clearance of transfused platelet concentrates. Transfusion 2004, 44:1487-1495.
140. Rinder H.M., Smith B.R. In vitro evaluation of stored platelets: is there hope for predicting posttransfusion platelet survival and function?. Transfusion 2003, 43:2-6.
141. Stohlawetz P., Horvath M., Pernerstorfer T., Nguyen H., Vondrovec B., Robisch A., et al. Effects of nitric oxide on platelet activation during plateletpheresis and in-vivo tracking of biotinylated platelets in humans. Transfusion 1999, 39:506-514.
142. Berger G., Hartwell D.W., Wagner D.D. P-selectin and platelet clearance. Blood 1998, 92:4446-4452.
143. Michelson A.D., Barnard M.R., Hechtman H.B., MacGregor H., Connolly R.J., Loscalzo J., et al. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci USA 1996, 93:11877-11882.
144. Kostelijk E.H., Fijnheer R., Nieuwenhuis H.K., Gouwerok C.W., de Korte D. Soluble P-selectin as parameter for platelet activation during storage. Thromb Haemost 1996, 76:1086-1089.
145. Bonello L., Camoin-Jau L., Armero S., Com O., Arques S., Burignat-Bonello C., et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009, 103:5-10.
146. Darzynkiewicz Z., Bedner E., Smolewski P. Flow cytometry in analysis of cell cycle and apoptosis. Seminars Hematol 2001, 38:179-193.
147. Verhoeven A.J., Verhaar R., Gouwerok E.G., de Korte D. The mitochondrial membrane potential in human platelets: a sensitive parameter for platelet quality. Transfusion 2005, 45:82-89.
148. Murphy S. Platelet storage for transfusion. Semin Hematol 1985, 22:165-177.
149. Snyder E.L., Beardsley D.S., Smith B.R. Storage of platelet concentrates after high-dose ultraviolet B irradiation. Transfusion 1991, 31:491-496.
150. Li J., Goodrich L., Hansen E., Edrich E., Gampp D., Goodrich R.P. Platelet glycolytic flux increases stimulated by ultraviolet-induced stress is not the direct cause of platelet morphology and activation changes: possible implications for the role of glucose in platelet storage. Transfusion 2005, 45:1750-1758.
151. Kroemer G., Petit P.X., Zanzami N., Vayssiere J.L., Mignotte B. The biochemistry of apoptosis. FASEB J 1995, 9:1277-1287.
152. Heerde van W.L., Robert-Offerman S., Dumont E., Hofstra L., Doevendans P.A., Smits J.F.M., et al. Markers of apoptosis in cardiovascular tissue. Focus on Annexin V. Cardiovasc Res 2000, 45:449-549.
153. Perrotta P.L., Perrotta C.L., Snyder E.L. Apoptotic activity in stored human platelets. Transfusion 2003, 43:526-535.
154. Leytin V., Freedman J. Platelet apoptosis in stored platelet concentrates and other models. Transfus Apher Sci 2003, 28:285-295.
155. Slichter S.J., Kaufman R.M., Assmann S.F., McCullough J., Triulzi D.J., Strauss R.G., et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010, 362:600-613.